These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 16463405)

  • 21. How European regulators view foreign data in the approval process.
    Breckenridge A; Hudson I
    Clin Pharmacol Ther; 2008 Sep; 84(3):311-2. PubMed ID: 18714321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New clinical trials policy at FDA.
    Vastag B
    Nat Biotechnol; 2006 Sep; 24(9):1043. PubMed ID: 16964196
    [No Abstract]   [Full Text] [Related]  

  • 23. How pharmaceuticals are developed.
    Vander Elst E
    J Am Dent Assoc; 1994 Jan; 125 Suppl():40S-44S. PubMed ID: 8294674
    [No Abstract]   [Full Text] [Related]  

  • 24. Clinical trials in India: balancing economic opportunity with the public health context.
    Dandona L
    Natl Med J India; 2006; 19(2):57-9. PubMed ID: 16756189
    [No Abstract]   [Full Text] [Related]  

  • 25. [Marketing authorization for pharmaceuticals: the necessity of European collaboration].
    Seitz R; Enzmann H
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):703-4. PubMed ID: 18592336
    [No Abstract]   [Full Text] [Related]  

  • 26. The changing timetable for the evaluation of new products for formulary consideration.
    Giaquinta D
    Manag Care Interface; 2003 Feb; 16(2):24-5, 28. PubMed ID: 12647522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A model for structured introduction of new drugs. The aim is to offer all patients appropriate treatment].
    Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergen-Dahl GT; Wilking N
    Lakartidningen; 2008 Oct 15-21; 105(42):2917-22. PubMed ID: 19025148
    [No Abstract]   [Full Text] [Related]  

  • 28. The EPA's new chemicals program under TSCA.
    Culleen LE
    Qual Assur; 1993; 2(1-2):121-6. PubMed ID: 8156198
    [No Abstract]   [Full Text] [Related]  

  • 29. Executed Chinese drug czar corrupted by system, observers say.
    Cyranoski D
    Nat Med; 2007 Aug; 13(8):889. PubMed ID: 17679990
    [No Abstract]   [Full Text] [Related]  

  • 30. Drugs in 2001: a number of ruses unveiled.
    Prescrire Int; 2002 Apr; 11(58):58-60. PubMed ID: 11987319
    [No Abstract]   [Full Text] [Related]  

  • 31. Researchers see a need for speed in EU trial approvals.
    Cressey D
    Nat Med; 2008 Aug; 14(8):794. PubMed ID: 18685580
    [No Abstract]   [Full Text] [Related]  

  • 32. A future for regulatory science in the European Union: the European Medicines Agency's strategy.
    Hines PA; Janssens R; Gonzalez-Quevedo R; Lambert AIOM; Humphreys AJ
    Nat Rev Drug Discov; 2020 May; 19(5):293-294. PubMed ID: 32235873
    [No Abstract]   [Full Text] [Related]  

  • 33. [Two years with EMEA: towards a unified drug registration within the EEC].
    Lennholm B
    Lakartidningen; 1997 Jan; 94(1-2):8-12. PubMed ID: 9053613
    [No Abstract]   [Full Text] [Related]  

  • 34. [Children on the drug development map. The Danish Society of Clinical Pharmacology].
    Thirstrup S; Heisterberg J;
    Ugeskr Laeger; 2008 Mar; 170(12):1039. PubMed ID: 18397657
    [No Abstract]   [Full Text] [Related]  

  • 35. The International Conference on Harmonization common technical document--global submission format?
    Molzon JA
    Food Drug Law J; 2005; 60(3):447-51. PubMed ID: 16304749
    [No Abstract]   [Full Text] [Related]  

  • 36. [False innovations in clinical research].
    Garattini S; Bertele' V
    Recenti Prog Med; 2006 Nov; 97(11):611-7. PubMed ID: 17252717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. How to systematically evaluate immunogenicity of therapeutic proteins - regulatory considerations.
    Jahn EM; Schneider CK
    N Biotechnol; 2009 Jun; 25(5):280-6. PubMed ID: 19491045
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Update and evaluation of Australian guidelines. Industry perspective.
    Carmine B
    Med Care; 1996 Dec; 34(12 Suppl):DS226-32. PubMed ID: 8969330
    [No Abstract]   [Full Text] [Related]  

  • 39. The unfinished business of U.S. drug safety regulation.
    Evans BJ; Flockhart DA
    Food Drug Law J; 2006; 61(1):45-63. PubMed ID: 16838457
    [No Abstract]   [Full Text] [Related]  

  • 40. An overview of the drug development process.
    Tonkens R
    Physician Exec; 2005; 31(3):48-52. PubMed ID: 16048163
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.